close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Rhythm Pharmaceuticals, Inc.

< Previous 1 2 3 4 5 Next >
News headline image
Rhythm Pharmaceuticals Presents New Data at ESPE 2023
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals Receives Orphan Drug Designation from European Medicines Agency for Setmelanotide for Treatment of Acquired Hypothalamic Obesity
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals Announces Update to September Conference Participation
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals Announces New ICD-10 Diagnosis Code Established for Bardet-Biedl Syndrome
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals to Present at Investor Conferences in September
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals Announces Pre-Marketing Early Access Authorization for Setmelanotide for Use in Patients with Hypothalamic Obesity in France
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Update
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals Announces Two Publications Detailing Burden of Hyperphagia and Obesity on Patients and Caregivers Living with Bardet-Biedl Syndrome
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals to Report Second Quarter 2023 Financial Results on Tuesday, August 1, 2023
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals Presents Data Demonstrating BMI Reduction in Patients with Hypothalamic Obesity Treated with Setmelanotide over Six Months at ENDO 2023
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals and Genpharm Announce Collaboration to Provide IMCIVREE® (setmelanotide) to Patients in Gulf Cooperation Council Countries
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® Setmelanotide Injection for Weight Management in Bardet-Biedl Syndrome or Genetically-confirmed Biallelic POMC, PCSK1, or LEPR Deficiency
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Update
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Germany for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals to Report First Quarter 2023 Financial Results on Tuesday, May 2, 2023
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals to Present at 22nd Annual Needham Virtual Healthcare Conference
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals Announces Publication of Bardet-Biedl Syndrome Patient and Caregiver Perspectives of Hunger and Quality of Life with Setmelanotide
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals Announces Acquisition of Xinvento B.V. and Portfolio of Investigational Therapeutics
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Wednesday, March 1, 2023
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals Announces Publication of Analysis of Quality of Life Improvements from Phase 3 Clinical Trial in Bardet-Biedl Syndrome
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.